oxonic acid has been researched along with Carcinoma, Non-Small Cell Lung in 157 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to analyze the safety and feasibility of low-dose apatinib combined with S-1 as a second-line therapy or beyond in Chinese patients with pulmonary and/or hepatic metastases of nasopharyngeal carcinoma (NPC)." | 7.96 | Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma. ( Chen, J; Huang, X; Lin, J; Wu, G; Zhang, S; Zhou, L, 2020) |
| "Combination chemotherapy consisting of carboplatin plus S-1 and concurrent TRT had a promising efficacy in elderly patients with locally advanced NSCLC; however, radiation pneumonitis was frequently observed." | 5.30 | Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study. ( Akimoto, T; Goto, K; Hida, T; Hosomi, Y; Nihei, K; Niho, S; Ohe, Y; Okamoto, H; Tanaka, H; Umemura, S, 2019) |
| "The purpose of this study was to analyze the safety and feasibility of low-dose apatinib combined with S-1 as a second-line therapy or beyond in Chinese patients with pulmonary and/or hepatic metastases of nasopharyngeal carcinoma (NPC)." | 3.96 | Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma. ( Chen, J; Huang, X; Lin, J; Wu, G; Zhang, S; Zhou, L, 2020) |
| "We report the development of spinal infarction during adjuvant chemotherapy with tegafur, gimeracil and oteracil (TS-1) after surgery for lung adenocarcinoma." | 3.79 | Spinal infarction related to the adjuvant chemotherapy for surgically resected non-small cell lung cancer: report of a case. ( Kawamura, M; Matsutani, N, 2013) |
| "The purpose of this trial is to evaluate the efficacy and safety of anlotinib combined with S-1 as the third-line treatment for patients with stage IV NSCLC." | 2.90 | Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial. ( Du, X; Geng, L; Wen, Y; Xiang, M; Yang, X, 2019) |
| "S-1 plus cisplatin in combination with bevacizumab met the primary endpoint in patients with advanced NSq-NSCLC." | 2.90 | Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202). ( Aono, H; Fujimoto, S; Gemma, A; Hosomi, Y; Isobe, H; Kubota, K; Minato, K; Miyanaga, A; Okamoto, H; Okuma, Y; Satouchi, M; Takiguchi, Y, 2019) |
| "Sixteen patients (48." | 2.87 | A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. ( Atagi, S; Azuma, M; Goto, H; Haku, T; Hanibuchi, M; Kakiuchi, S; Kawano, H; Kondo, M; Nishioka, Y; Nokihara, H; Ogushi, F; Otsuka, K; Sakaguchi, S; Shimizu, E; Toyoda, Y, 2018) |
| " The purpose of the current study was to identify which of the adverse events (AEs) contributed to the deterioration of QOL." | 2.82 | Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer. ( Aotani, E; Gemma, A; Hamano, T; Kobayashi, K; Takebayashi, T; Takeuchi, M, 2016) |
| "Irinotecan was administered at 60 mg/m(2) on Days 1 and 8." | 2.80 | A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. ( Arai, D; Betsuyaku, T; Ikemura, S; Ishioka, K; Kabata, H; Kamata, H; Kawada, I; Miyata, J; Naoki, K; Ohgino, K; Sato, T; Soejima, K; Terai, H; Yasuda, H; Yoda, S, 2015) |
| "Both amrubicin (Am) and S-1 are effective against non-small-cell lung cancer (NSCLC), and preclinical studies have demonstrated that the effect of tegafur/uracil, the original compound of S-1, in combination with Am significantly inhibits tumor growth." | 2.78 | Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. ( Kondo, T; Murakami, S; Oshita, F; Saito, H; Sugiura, M; Yamada, K, 2013) |
| " We investigated the activity and toxicity of S-1 in combination with cisplatin in patients with unresectable non-small cell lung cancer (NSCLC)." | 2.76 | An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. ( Baggstrom, M; Graham, C; Herbst, R; Jones, D; Saito, K; Sandler, A; Zergebel, C, 2011) |
| "This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1 in chemo-naïve non-small cell lung cancer patients." | 2.75 | Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer. ( Ando, M; Funada, Y; Hata, A; Katakami, N; Kotani, Y; Negoro, S; Satouchi, M; Shimada, T; Urata, Y; Yoshimura, S, 2010) |
| " To determine the feasibility of S-1 combined with weekly irinotecan for patients with advanced NSCLC, we performed a phase I study to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of irinotecan." | 2.74 | Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer. ( Honda, Y; Ishida, T; Ishimoto, O; Munakata, M; Sugawara, S, 2009) |
| " S-1 was administered orally at the dosage decided by using the nomogram based on patient BSA b." | 2.74 | A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. ( Hayashi, M; Hoshino, T; Imizu, H; Kato, A; Kohashi, Y; Mieno, Y; Okazawa, M; Saito, Y; Sakakibara, H; Tada, T; Takeuchi, Y; Totani, Y; Uchiyama, Y; Yoneda, Y, 2009) |
| "Grade 4 neutropenia was observed in one of the 59 patients (1." | 2.72 | [Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer]. ( Kawahara, M; Yumine, K, 2006) |
| "Grade 4 neutropenia was observed in one of the 59 patients (1." | 2.70 | Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. ( Furuse, K; Hasegawa, K; Kawahara, M; Kudoh, S; Matsui, K; Niitani, H; Segawa, Y; Yoshimori, K, 2001) |
| "Lung cancer is the leading cause of cancer-related deaths in the world, and non-small cell lung cancer accounts for > 75% of all lung cancer cases." | 2.58 | S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol. ( Hu, T; Liu, F; Wang, C; Wang, W, 2018) |
| "Lung cancer is the leading cause of cancer-related death throughout the world including Japan." | 2.43 | [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents]. ( Masuda, N; Yanase, N; Yokoba, M, 2005) |
| " The baseline characteristics of the patients, response to S-1 monotherapy, and adverse events (AEs) were investigated, retrospectively." | 1.56 | Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis. ( Imai, H; Ishihara, S; Kaburagi, T; Kaira, K; Kanazawa, K; Kasahara, N; Kasai, T; Kishikawa, T; Minato, K; Minemura, H; Mori, K; Naruse, I; Shibata, Y; Suzuki, K; Uchino, J; Umeda, Y; Wasamoto, S; Yamada, Y; Yamaguchi, O, 2020) |
| " For them, we performed a pilot study to evaluate the feasibility of chemotherapy with carboplatin and S-1, which are known as cytotoxic drug with rare development of ILD as adverse event." | 1.43 | Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study. ( Baba, T; Hagiwara, E; Ikeda, S; Iwasawa, T; Kato, T; Komatsu, S; Ogura, T; Okuda, R; Satoh, H; Sekine, A; Shinohara, T, 2016) |
| "She was diagnosed with drug-induced thrombotic thrombocytopenic purpura (TTP)." | 1.39 | Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin. ( Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y, 2013) |
| "Gefitinib was administered postoperatively." | 1.36 | [A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient]. ( Fujimoto, H; Hashimoto, K; Ishizuka, H; Kameyama, Y; Oyama, T; Suito, T; Yasuda, H, 2010) |
| "Tegafur has been shown to be converted enzymatically to 5-FU to exert its antitumor effect, and this conversion is principally catalyzed by CYP2A6." | 1.35 | The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. ( Chida, K; Inui, N; Kaida, Y; Nakamura, H; Suda, T; Watanabe, H, 2008) |
| " Each course consisted of S-1 at a dosage of 100 mg/body/day, twice daily for 21 days, followed by 14 days of drug withdrawal." | 1.34 | [An advanced aged case of intrapulmonary metastasis of non-small cell lung cancer successfully controlled with S-1 capsule therapy alone for an extended period]. ( Katayama, T; Watari, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (21.02) | 29.6817 |
| 2010's | 115 (73.25) | 24.3611 |
| 2020's | 9 (5.73) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, M | 1 |
| Kusumoto, H | 1 |
| Shiono, H | 1 |
| Shintani, Y | 1 |
| Ose, N | 1 |
| Sakamaki, Y | 1 |
| Okami, J | 1 |
| Higashiyama, M | 1 |
| Takeuchi, Y | 2 |
| Roviello, G | 1 |
| Nobili, S | 1 |
| Mini, E | 1 |
| Tsukita, Y | 1 |
| Inoue, A | 3 |
| Sugawara, S | 7 |
| Kuyama, S | 3 |
| Nakagawa, T | 1 |
| Harada, D | 2 |
| Tanaka, H | 4 |
| Watanabe, K | 3 |
| Mori, Y | 1 |
| Harada, T | 3 |
| Hino, T | 1 |
| Fujii, M | 4 |
| Ichinose, M | 1 |
| Lai, CL | 1 |
| Wei, YF | 1 |
| Hsia, TC | 1 |
| Chang, GC | 1 |
| Wu, JT | 1 |
| Chen, JY | 1 |
| Chen, YM | 1 |
| Yang, X | 1 |
| Xiang, M | 1 |
| Geng, L | 1 |
| Wen, Y | 1 |
| Du, X | 1 |
| Kasai, T | 5 |
| Mori, K | 3 |
| Kishi, K | 4 |
| Kaburagi, T | 3 |
| Hosomi, Y | 5 |
| Imai, H | 6 |
| Yamada, Y | 3 |
| Yomota, M | 1 |
| Moriguchi, S | 1 |
| Seike, M | 2 |
| Minato, K | 6 |
| Gemma, A | 9 |
| Kato, R | 1 |
| Hayashi, H | 2 |
| Chiba, Y | 1 |
| Miyawaki, E | 1 |
| Shimizu, J | 2 |
| Ozaki, T | 2 |
| Fujimoto, D | 1 |
| Toyozawa, R | 1 |
| Nakamura, A | 4 |
| Kozuki, T | 3 |
| Tanaka, K | 2 |
| Teraoka, S | 1 |
| Usui, K | 1 |
| Nishino, K | 4 |
| Hataji, O | 1 |
| Ota, K | 1 |
| Ebi, N | 4 |
| Saeki, S | 2 |
| Akazawa, Y | 2 |
| Okuno, M | 2 |
| Yamamoto, N | 15 |
| Nakagawa, K | 18 |
| Zhou, L | 1 |
| Lin, J | 1 |
| Wu, G | 1 |
| Chen, J | 2 |
| Huang, X | 1 |
| Zhang, S | 1 |
| Tabe, C | 1 |
| Okumura, F | 1 |
| Shiratori, T | 1 |
| Ishioka, Y | 1 |
| Itoga, M | 1 |
| Taima, K | 1 |
| Morimoto, T | 2 |
| Kimura, D | 1 |
| Tsushima, T | 1 |
| Tasaka, S | 1 |
| Minemura, H | 1 |
| Kishikawa, T | 1 |
| Suzuki, K | 3 |
| Umeda, Y | 1 |
| Wasamoto, S | 1 |
| Kasahara, N | 1 |
| Ishihara, S | 1 |
| Yamaguchi, O | 1 |
| Naruse, I | 1 |
| Uchino, J | 1 |
| Kanazawa, K | 1 |
| Shibata, Y | 1 |
| Kaira, K | 9 |
| Shimokawa, T | 1 |
| Yamada, K | 3 |
| Kubota, K | 6 |
| Takiguchi, Y | 5 |
| Saito, H | 3 |
| Kato, T | 3 |
| Otani, S | 2 |
| Nakamura, Y | 8 |
| Misumi, T | 1 |
| Yamanaka, T | 7 |
| Okamoto, H | 6 |
| Takemoto, S | 1 |
| Akagi, K | 1 |
| Ono, S | 1 |
| Tomono, H | 2 |
| Honda, N | 1 |
| Suyama, T | 1 |
| Umeyama, Y | 1 |
| Dotsu, Y | 1 |
| Taniguchi, H | 5 |
| Ogawara, D | 2 |
| Senju, H | 1 |
| Gyotoku, H | 1 |
| Sugasaki, N | 1 |
| Yamaguchi, H | 5 |
| Nakatomi, K | 2 |
| Fukuda, M | 4 |
| Mukae, H | 2 |
| Nishijima-Futami, Y | 1 |
| Minami, S | 3 |
| Futami, S | 1 |
| Koba, T | 2 |
| Higashiguchi, M | 1 |
| Tamiya, M | 2 |
| Suzuki, H | 4 |
| Hirashima, T | 8 |
| Komuta, K | 4 |
| Kijima, T | 5 |
| Liu, D | 1 |
| Nakashima, N | 1 |
| Nakano, J | 1 |
| Tarumi, S | 1 |
| Matsuura, N | 1 |
| Nakano, T | 3 |
| Nii, K | 1 |
| Tokunaga, Y | 1 |
| Go, T | 1 |
| Yokomise, H | 1 |
| Niho, S | 3 |
| Ohe, Y | 4 |
| Ohmatsu, H | 2 |
| Umemura, S | 2 |
| Matsumoto, S | 3 |
| Yoh, K | 2 |
| Goto, K | 6 |
| Hata, Y | 1 |
| Kiribayashi, T | 1 |
| Nagashima, M | 1 |
| Nakayama, T | 1 |
| Ikeda, S | 2 |
| Kadokura, M | 1 |
| Ozeki, Y | 1 |
| Otsuka, H | 1 |
| Murakami, Y | 1 |
| Takagi, K | 1 |
| Iyoda, A | 1 |
| Wang, J | 2 |
| Wu, X | 1 |
| Che, X | 1 |
| Zou, Y | 1 |
| Weng, M | 1 |
| Miao, Q | 1 |
| Zheng, Q | 1 |
| Nokihara, H | 4 |
| Lu, S | 1 |
| Mok, TSK | 1 |
| Shi, YK | 1 |
| Zhang, L | 1 |
| Soo, RA | 1 |
| Yang, JC | 1 |
| Nishio, M | 6 |
| Takahashi, T | 10 |
| Chang, J | 1 |
| Maemondo, M | 2 |
| Ichinose, Y | 15 |
| Cheng, Y | 1 |
| Lim, WT | 1 |
| Morita, S | 7 |
| Tamura, T | 3 |
| Goto, H | 2 |
| Okano, Y | 2 |
| Machida, H | 1 |
| Hatakeyama, N | 1 |
| Ogushi, F | 2 |
| Haku, T | 2 |
| Kanematsu, T | 1 |
| Urata, T | 1 |
| Kakiuchi, S | 2 |
| Hanibuchi, M | 2 |
| Sone, S | 1 |
| Nishioka, Y | 2 |
| Konishi, M | 1 |
| Imai, A | 1 |
| Sugimoto, K | 1 |
| Katakami, N | 7 |
| Imai, Y | 1 |
| Kamoshida, S | 1 |
| Cui, J | 1 |
| Wang, MC | 1 |
| Zhang, YM | 1 |
| Ren, MZ | 1 |
| Wang, SX | 1 |
| Nan, KJ | 1 |
| Song, LP | 1 |
| Tsuboi, M | 3 |
| Kondo, K | 1 |
| Takizawa, H | 1 |
| Kawakita, N | 1 |
| Sawada, T | 1 |
| Toba, H | 1 |
| Kawakami, Y | 1 |
| Yoshida, M | 2 |
| Ishikura, H | 1 |
| Kimura, S | 1 |
| Tangoku, A | 1 |
| Liu, F | 1 |
| Wang, C | 1 |
| Hu, T | 1 |
| Wang, W | 2 |
| Yang, L | 1 |
| Yang, S | 1 |
| Liu, Y | 1 |
| Li, J | 1 |
| Hu, X | 1 |
| Wang, Y | 2 |
| Zhang, Y | 1 |
| Zhao, D | 2 |
| Feng, JF | 1 |
| Wang, XH | 1 |
| Yin, Y | 1 |
| Wu, B | 1 |
| Huang, Z | 1 |
| Zhuang, W | 1 |
| Xu, Z | 1 |
| Huang, C | 1 |
| Huang, Y | 1 |
| Zhang, J | 1 |
| Sasaki, T | 4 |
| Seto, T | 11 |
| Kunitake, N | 1 |
| Kodaira, T | 1 |
| Kozuka, T | 3 |
| Harada, H | 5 |
| Yoshimura, N | 1 |
| Tsutsumi, S | 1 |
| Kitajima, H | 1 |
| Kataoka, M | 2 |
| Nishimura, Y | 4 |
| Nakanishi, Y | 4 |
| Okamoto, T | 1 |
| Yano, T | 3 |
| Shimokawa, M | 1 |
| Takeo, S | 2 |
| Yamazaki, K | 2 |
| Sugio, K | 3 |
| Takenoyama, M | 2 |
| Nagashima, A | 1 |
| Tsukamoto, S | 2 |
| Hamatake, M | 3 |
| Yokoyama, H | 1 |
| Ueda, H | 1 |
| Motohiro, A | 1 |
| Tagawa, T | 4 |
| Shoji, F | 2 |
| Kometani, T | 3 |
| Saito, G | 1 |
| Fukuyama, Y | 1 |
| Toyokawa, G | 2 |
| Osoegawa, A | 1 |
| Emi, Y | 1 |
| Maehara, Y | 2 |
| Atagi, S | 8 |
| Shimizu, E | 2 |
| Toyoda, Y | 1 |
| Azuma, M | 1 |
| Kondo, M | 2 |
| Kawano, H | 1 |
| Otsuka, K | 1 |
| Sakaguchi, S | 1 |
| Qie, S | 1 |
| Li, Y | 1 |
| Shi, HY | 1 |
| Yuan, L | 1 |
| Zhang, X | 1 |
| Soda, H | 1 |
| Fukuda, Y | 1 |
| Okuno, D | 1 |
| Koga, S | 1 |
| Umemura, A | 1 |
| Tsuchiya, T | 5 |
| Matsumoto, K | 4 |
| Miyazaki, T | 3 |
| Yamazaki, T | 1 |
| Sano, I | 2 |
| Fukuoka, J | 1 |
| Yamasaki, N | 3 |
| Nagayasu, T | 3 |
| Yokoi, T | 1 |
| Shiroyama, T | 4 |
| Torii, Y | 1 |
| Sugimoto, H | 1 |
| Niki, M | 1 |
| Mori, M | 7 |
| Morimura, O | 1 |
| Akiyama, N | 1 |
| Karayama, M | 1 |
| Inui, N | 3 |
| Yasui, H | 1 |
| Hozumi, H | 1 |
| Suzuki, Y | 1 |
| Furuhashi, K | 1 |
| Fujisawa, T | 1 |
| Enomoto, N | 1 |
| Inami, N | 1 |
| Matsuura, S | 1 |
| Kaida, Y | 2 |
| Uto, T | 1 |
| Matsui, T | 1 |
| Asada, K | 1 |
| Matsuda, H | 1 |
| Toyoshima, M | 1 |
| Suda, T | 3 |
| Sakai, H | 7 |
| Imamura, F | 5 |
| Shingyoji, M | 1 |
| Saka, H | 5 |
| Takeda, K | 10 |
| Okamoto, I | 14 |
| Kiura, K | 7 |
| Tamura, N | 1 |
| Horinouchi, H | 2 |
| Sekine, K | 1 |
| Matsumoto, Y | 1 |
| Murakami, S | 2 |
| Goto, Y | 1 |
| Kanda, S | 2 |
| Fujiwara, Y | 2 |
| Nihei, K | 1 |
| Hida, T | 1 |
| Akimoto, T | 1 |
| Han, L | 1 |
| Wei, ZX | 1 |
| Lv, YF | 1 |
| Jiang, AY | 1 |
| Miyanaga, A | 2 |
| Okuma, Y | 1 |
| Fujimoto, S | 1 |
| Satouchi, M | 8 |
| Isobe, H | 3 |
| Aono, H | 1 |
| Matsutani, N | 1 |
| Kawamura, M | 1 |
| Murakami, H | 5 |
| Ohyanagi, F | 2 |
| Ishikura, S | 1 |
| Naito, T | 4 |
| Horiike, A | 2 |
| Nishimura, T | 5 |
| Urata, Y | 4 |
| Takeda, M | 3 |
| Hattori, Y | 3 |
| Okuno, K | 1 |
| Shimada, T | 3 |
| Kurata, T | 4 |
| Kaneda, H | 2 |
| Miyazaki, M | 5 |
| Terashima, M | 2 |
| Negoro, S | 4 |
| Nishijima, Y | 1 |
| Hirata, H | 1 |
| Himeno, A | 1 |
| Kida, H | 1 |
| Matsumoto, M | 1 |
| Takahashi, R | 1 |
| Otani, Y | 1 |
| Inoue, K | 2 |
| Nagatomo, I | 1 |
| Takeda, Y | 1 |
| Tachibana, I | 3 |
| Fujimura, Y | 1 |
| Kumanogoh, A | 2 |
| Komazaki, Y | 1 |
| Sakashita, H | 1 |
| Furuiye, M | 1 |
| Fujie, T | 1 |
| Tamaoka, M | 1 |
| Sumi, Y | 1 |
| Miyazaki, Y | 1 |
| Kojima, K | 1 |
| Jin, Y | 1 |
| Inase, N | 2 |
| Ikeda, N | 3 |
| Michimae, H | 2 |
| Shimizu, K | 6 |
| Oshita, F | 2 |
| Kunitoh, H | 4 |
| Takeuchi, M | 3 |
| Yamaguchi, M | 1 |
| Ohba, T | 3 |
| Hirai, F | 2 |
| Taguchi, K | 1 |
| Yokosuka, T | 1 |
| Kobayashi, T | 1 |
| Enomoto, T | 1 |
| Takeda, A | 1 |
| Tomizawa, Y | 5 |
| Yoshino, R | 1 |
| Yoshii, A | 2 |
| Matsuura, M | 1 |
| Iwasaki, Y | 2 |
| Koga, Y | 2 |
| Ono, A | 3 |
| Nishioka, M | 1 |
| Kamide, Y | 2 |
| Hisada, T | 6 |
| Ishizuka, T | 6 |
| Shirai, K | 1 |
| Ebara, T | 2 |
| Saitoh, J | 1 |
| Sunaga, N | 6 |
| Miyoshi, S | 2 |
| Ito, R | 1 |
| Katayama, H | 1 |
| Kadowaki, T | 1 |
| Yano, S | 1 |
| Watanabe, A | 1 |
| Abe, M | 1 |
| Hamada, H | 1 |
| Okura, T | 1 |
| Higaki, J | 1 |
| Sakai, K | 2 |
| Yoshioka, H | 6 |
| Kogure, Y | 1 |
| Kimura, T | 1 |
| Sawa, T | 4 |
| Yamamoto, M | 4 |
| Nagase, S | 1 |
| Takayama, K | 1 |
| Tomii, K | 1 |
| Maeda, T | 3 |
| Oizumi, S | 2 |
| Fujii, S | 1 |
| Akashi, Y | 1 |
| Nishio, K | 4 |
| Tang, Y | 1 |
| Teng, XZ | 1 |
| Shi, L | 1 |
| Kawahara, M | 6 |
| Aoe, K | 4 |
| Takigawa, N | 5 |
| Hotta, K | 6 |
| Kishino, D | 3 |
| Nogami, N | 5 |
| Tabata, M | 5 |
| Harita, S | 3 |
| Okada, T | 2 |
| Kubo, T | 1 |
| Hosokawa, S | 3 |
| Fujiwara, K | 2 |
| Gemba, K | 4 |
| Yasugi, M | 1 |
| Kato, Y | 2 |
| Katsui, K | 2 |
| Kanazawa, S | 4 |
| Ueoka, H | 4 |
| Tanimoto, M | 5 |
| Masago, K | 1 |
| Fujita, S | 1 |
| Hata, A | 3 |
| Kaji, R | 1 |
| Ohtsuka, K | 1 |
| Okuda, C | 2 |
| Takeshita, J | 1 |
| Segawa, Y | 4 |
| Oze, I | 1 |
| Shibayama, T | 1 |
| Takemoto, M | 3 |
| Yao, L | 1 |
| Xu, S | 1 |
| Xu, J | 2 |
| Yang, C | 1 |
| Sun, D | 1 |
| Izumi, H | 1 |
| Touge, H | 1 |
| Igishi, T | 1 |
| Makino, H | 1 |
| Nishii-Ito, S | 1 |
| Takata, M | 1 |
| Nakazaki, H | 1 |
| Ueda, Y | 1 |
| Kodani, M | 1 |
| Kurai, J | 1 |
| Sakamoto, T | 1 |
| Yanai, M | 2 |
| Tanaka, N | 1 |
| Nirodi, CS | 1 |
| Ikemura, S | 2 |
| Naoki, K | 2 |
| Yasuda, H | 4 |
| Kawada, I | 2 |
| Yoda, S | 2 |
| Terai, H | 2 |
| Sato, T | 3 |
| Ishioka, K | 1 |
| Arai, D | 1 |
| Ohgino, K | 1 |
| Kamata, H | 1 |
| Miyata, J | 1 |
| Kabata, H | 1 |
| Betsuyaku, T | 1 |
| Soejima, K | 2 |
| Tamiya, A | 2 |
| Saijo, N | 3 |
| Nakatani, T | 1 |
| Minomo, S | 1 |
| Tsuji, T | 1 |
| Takeuchi, N | 1 |
| Omachi, N | 1 |
| Kurata, K | 1 |
| Okamoto, N | 1 |
| Okishio, K | 3 |
| Hishida, T | 1 |
| Shukuya, T | 5 |
| Takamochi, K | 1 |
| Sakurai, H | 2 |
| Ohashi, Y | 2 |
| Numata, T | 1 |
| Osawa, H | 1 |
| Homma, Y | 1 |
| Yanai, H | 1 |
| Endo, T | 1 |
| Kobayashi, K | 3 |
| Yokoyama, A | 1 |
| Kudoh, S | 7 |
| Kumagai, T | 2 |
| Tachihara, M | 1 |
| Yokota, S | 1 |
| Kaneda, T | 1 |
| Iwamoto, Y | 3 |
| Mitsudomi, T | 1 |
| Takahama, M | 1 |
| Yoshimura, M | 1 |
| Yoshino, I | 2 |
| Kawaguchi, T | 3 |
| Ohta, M | 1 |
| Okada, M | 1 |
| Mouri, A | 1 |
| Hamamoto, Y | 1 |
| Kameyama, N | 1 |
| Ibe, T | 1 |
| Takeoka, S | 1 |
| Honma, C | 1 |
| Fukusumi, M | 1 |
| Kamimura, M | 1 |
| Arai, J | 1 |
| Honda, S | 1 |
| Akamine, S | 3 |
| Muraoka, M | 1 |
| Hisano, H | 2 |
| Kitazaki, T | 1 |
| Nagashima, S | 1 |
| Takatani, H | 1 |
| Nakano, H | 1 |
| Ikeda, T | 1 |
| Tsukamoto, K | 1 |
| Oka, M | 1 |
| Kohno, S | 1 |
| Iwata, T | 1 |
| Nakajima, T | 1 |
| Yoshida, S | 1 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Aotani, E | 1 |
| Hamano, T | 1 |
| Takebayashi, T | 1 |
| Torigoe, H | 1 |
| Toyooka, S | 2 |
| Soh, J | 2 |
| Maki, Y | 1 |
| Sekine, A | 1 |
| Satoh, H | 1 |
| Baba, T | 1 |
| Okuda, R | 1 |
| Shinohara, T | 1 |
| Komatsu, S | 1 |
| Hagiwara, E | 1 |
| Iwasawa, T | 1 |
| Ogura, T | 1 |
| Okumura, N | 1 |
| Nakata, M | 1 |
| Nakamura, H | 3 |
| Kajiwara, S | 1 |
| Sano, Y | 1 |
| Aoe, M | 1 |
| Kataoka, K | 2 |
| Matsuo, K | 2 |
| Date, H | 2 |
| Ichiki, M | 1 |
| Takahashi, K | 2 |
| Hisamatsu, Y | 1 |
| Takeoka, H | 1 |
| Azuma, K | 2 |
| Nishikawa, K | 1 |
| Tokito, T | 1 |
| Ishii, H | 1 |
| Hoshino, T | 2 |
| Takase, N | 1 |
| Kiriu, T | 1 |
| Itoh, S | 1 |
| Kawa, Y | 1 |
| Tsujino, K | 1 |
| Soejima, T | 1 |
| Feng, J | 1 |
| Wang, X | 1 |
| Sun, X | 1 |
| Sun, L | 1 |
| Zhang, SL | 1 |
| Xiong, ZC | 1 |
| Ma, JT | 1 |
| Han, CB | 1 |
| Yanagitani, N | 5 |
| Aoki, H | 1 |
| Kawata, T | 4 |
| Utsugi, M | 5 |
| Shimizu, Y | 2 |
| Ozawa, Y | 1 |
| Naitoh, T | 1 |
| Yasuda, K | 1 |
| Nagayama, M | 1 |
| Shirai, T | 2 |
| Suganuma, H | 1 |
| Chida, K | 2 |
| Kubo, A | 2 |
| Fukuoka, M | 11 |
| Kusunoki, Y | 1 |
| Takada, M | 3 |
| Uehira, K | 1 |
| Yumine, K | 2 |
| Saito, R | 4 |
| Fukai, S | 1 |
| Komatsu, H | 1 |
| Zeng, L | 1 |
| Ou, G | 1 |
| Itasaka, S | 1 |
| Xie, X | 1 |
| Shibuya, K | 1 |
| Kizaka-Kondoh, S | 1 |
| Morinibu, A | 1 |
| Shinomiya, K | 1 |
| Hiraoka, M | 1 |
| Kawamura, H | 1 |
| Nonaka, T | 1 |
| Ishikawa, H | 1 |
| Suga, T | 1 |
| Hara, K | 1 |
| Chikamori, K | 1 |
| Kamei, H | 1 |
| Takata, S | 2 |
| Okabe, T | 1 |
| Tsukioka, S | 1 |
| Uchida, J | 2 |
| Hatashita, E | 1 |
| Yoshida, T | 1 |
| Jänne, PA | 1 |
| Ishimoto, O | 1 |
| Ishida, T | 1 |
| Honda, Y | 1 |
| Munakata, M | 1 |
| Yamasaki, T | 1 |
| Endo, Y | 1 |
| Furuie, M | 1 |
| Ohtani, Y | 1 |
| Yoshizawa, Y | 1 |
| Totani, Y | 1 |
| Saito, Y | 1 |
| Hayashi, M | 1 |
| Tada, T | 1 |
| Kohashi, Y | 1 |
| Mieno, Y | 1 |
| Kato, A | 1 |
| Imizu, H | 1 |
| Yoneda, Y | 1 |
| Uchiyama, Y | 1 |
| Okazawa, M | 1 |
| Sakakibara, H | 1 |
| Kawano, O | 1 |
| Yano, M | 1 |
| Sasaki, H | 1 |
| Yukiue, H | 1 |
| Okuda, K | 3 |
| Fujii, Y | 1 |
| Maruyama, R | 3 |
| Tokunaga, S | 1 |
| Higashi, H | 1 |
| Tamura, K | 2 |
| Kashii, T | 1 |
| Kobayashi, M | 1 |
| Matsui, K | 2 |
| Shibata, T | 1 |
| Inagaki, M | 1 |
| Onuki, T | 1 |
| Iguchi, K | 1 |
| Ogata, T | 1 |
| Hayashi, Y | 1 |
| Saito, K | 3 |
| Wakai, Y | 1 |
| Takabe, K | 1 |
| Shinohara, Y | 1 |
| Ohtani, T | 1 |
| Horikoshi, K | 1 |
| Hashizume, T | 1 |
| Nakada, Y | 1 |
| Gomi, K | 1 |
| Morota, M | 1 |
| Endo, M | 3 |
| Tsuya, A | 4 |
| Horai, T | 1 |
| Iijima, H | 2 |
| Tsurumaki, H | 2 |
| Kobayashi, S | 1 |
| Fujino, N | 1 |
| Suzuki, S | 1 |
| Tada, Y | 1 |
| Hino, M | 1 |
| Yoshimori, K | 3 |
| Yoshimura, A | 2 |
| Nagao, K | 1 |
| Niitani, H | 5 |
| Takakuwa, O | 1 |
| Oguri, T | 1 |
| Sato, S | 1 |
| Nakao, M | 1 |
| Ohta, C | 1 |
| Iwashima, Y | 1 |
| Maeno, K | 1 |
| Kutsuna, T | 1 |
| Ueda, R | 1 |
| Okudera, K | 1 |
| Takanashi, S | 1 |
| Hayashi, A | 1 |
| Nakamura, K | 1 |
| Mikuniya, M | 1 |
| Dempoya, J | 1 |
| Okumura, K | 1 |
| Tanaka, F | 1 |
| Wada, H | 2 |
| Fukushima, M | 2 |
| Yanagihara, K | 1 |
| Yoshimura, K | 1 |
| Niimi, M | 1 |
| Ishiguro, H | 1 |
| Kitano, T | 1 |
| Kanai, M | 1 |
| Misawa, A | 1 |
| Tada, H | 1 |
| Teramukai, S | 1 |
| Mio, T | 1 |
| Kotani, Y | 1 |
| Yoshimura, S | 1 |
| Funada, Y | 1 |
| Ando, M | 4 |
| Ariyoshi, Y | 1 |
| Fujimoto, H | 2 |
| Oyama, T | 2 |
| Suito, T | 2 |
| Hashimoto, K | 1 |
| Kameyama, Y | 2 |
| Ishizuka, H | 1 |
| Igawa, S | 2 |
| Kaira, R | 1 |
| Nagano, T | 1 |
| Yasunaga, M | 1 |
| Kenmotsu, H | 2 |
| Kuroda, J | 1 |
| Sugino, T | 1 |
| Nishiwaki, Y | 1 |
| Matsumura, Y | 1 |
| Noro, R | 1 |
| Minegishi, Y | 1 |
| Okano, T | 1 |
| Soeno, C | 1 |
| Matsuda, K | 1 |
| Himei, K | 1 |
| Shinkai, T | 2 |
| Takezawa, K | 2 |
| Tanizaki, J | 1 |
| Kuwata, K | 1 |
| Oki, Y | 1 |
| Hirose, T | 2 |
| Yamaoka, T | 2 |
| Kusumoto, S | 1 |
| Sugiyama, T | 2 |
| Nakashima, M | 2 |
| Murata, Y | 1 |
| Ohmori, T | 1 |
| Adachi, M | 2 |
| Kawai, H | 1 |
| Asami, K | 1 |
| Suzuki, J | 1 |
| Watanabe, S | 1 |
| Sato, K | 1 |
| Seki, N | 1 |
| Eguchi, K | 2 |
| Nishikawa, M | 1 |
| Hirabayashi, N | 1 |
| Kitano, M | 1 |
| Watanabe, H | 2 |
| Nakachi, I | 1 |
| Satomi, R | 1 |
| Nakayama, S | 2 |
| Morosawa, M | 1 |
| Asano, K | 1 |
| Nishiyama, O | 1 |
| Kondoh, Y | 1 |
| Takada, K | 1 |
| Baba, K | 1 |
| Sugino, Y | 1 |
| Ogasawara, T | 1 |
| Imaizumi, K | 1 |
| Hasegawa, Y | 2 |
| Suzuki, R | 1 |
| Shimokata, K | 1 |
| Govindan, R | 1 |
| Morgensztern, D | 1 |
| Kommor, MD | 1 |
| Herbst, RS | 1 |
| Schaefer, P | 1 |
| Gandhi, J | 1 |
| Zergebel, C | 2 |
| Schiller, J | 1 |
| Kawase, I | 2 |
| Sandler, A | 1 |
| Graham, C | 1 |
| Baggstrom, M | 1 |
| Herbst, R | 1 |
| Jones, D | 1 |
| Higuchi, M | 1 |
| Shio, Y | 1 |
| Satoh, Y | 1 |
| Kitamura, M | 1 |
| Gotoh, M | 1 |
| Asahina, H | 1 |
| Sekine, I | 1 |
| Akie, K | 1 |
| Ogura, S | 1 |
| Shinagawa, N | 1 |
| Kikuchi, E | 1 |
| Fukumoto, S | 1 |
| Harada, M | 1 |
| Kinoshita, I | 1 |
| Kojima, T | 1 |
| Fujita, Y | 2 |
| Ohsaki, Y | 1 |
| Dosaka-Akita, H | 1 |
| Nishimura, M | 1 |
| Ondo, K | 1 |
| Tanaka, M | 1 |
| Wada, M | 1 |
| Ryuge, S | 1 |
| Nagashima, Y | 1 |
| Hayashi, N | 1 |
| Maki, S | 1 |
| Katono, K | 1 |
| Takakura, A | 1 |
| Yanaihara, T | 1 |
| Yokoba, M | 2 |
| Mitsufuji, H | 1 |
| Kubota, M | 1 |
| Katagiri, M | 1 |
| Masuda, N | 2 |
| Hayashihara, K | 1 |
| Takahashi, F | 1 |
| Matsumura, A | 1 |
| Tamura, A | 1 |
| Akamatsu, H | 1 |
| Sakaguchi, C | 1 |
| Shoji, T | 1 |
| Sonobe, M | 1 |
| Fujinaga, T | 1 |
| Chen, F | 1 |
| Miyahara, R | 1 |
| Bando, T | 1 |
| Minami, H | 1 |
| Taniguchi, Y | 1 |
| Tsurutani, J | 1 |
| Yonesaka, K | 1 |
| Morinaga, R | 1 |
| Kudoh, T | 1 |
| Nishikawa, T | 1 |
| Goya, H | 1 |
| Kuraishi, H | 1 |
| Koyama, S | 2 |
| Ichiyama, T | 1 |
| Yoshiike, F | 1 |
| Hirai, K | 1 |
| Agatsuma, T | 1 |
| Tateishi, K | 1 |
| Yamamoto, H | 1 |
| Kubo, K | 1 |
| Koizumi, T | 1 |
| Yamamoto, S | 1 |
| Ogata, Y | 1 |
| Okafuji, K | 1 |
| Komiyama, K | 1 |
| Minezaki, S | 1 |
| Kotajima, F | 1 |
| Sutani, A | 1 |
| Hoshi, E | 1 |
| Takayanagi, N | 1 |
| Nakayama, M | 1 |
| Kikuchi, K | 1 |
| Kato, M | 2 |
| Onishi, H | 1 |
| Tsuruta, N | 1 |
| Higuchi, K | 1 |
| Motoshita, J | 1 |
| Katano, M | 1 |
| Sugiura, M | 1 |
| Kondo, T | 1 |
| Kishimoto, J | 1 |
| Nagamatsu, Y | 1 |
| Aono, N | 1 |
| Ito, Y | 1 |
| Okuyama, T | 1 |
| Yoshinami, T | 1 |
| Nakai, Y | 1 |
| Sugiura, T | 2 |
| Yanase, N | 1 |
| Wataya, H | 1 |
| Katayama, T | 1 |
| Watari, M | 1 |
| Hosaka, T | 1 |
| Ishida, H | 1 |
| Ichikawa, W | 1 |
| Fujita, K | 1 |
| Sasaki, Y | 1 |
| Furuse, K | 2 |
| Hasegawa, K | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study[NCT04153734] | Phase 2 | 21 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Safety and Efficacy of Sequential Stereotactic Radiotherapy With S1 Combined With Endostar in the Treatment of Stage IV Lung Squamous Cell Carcinoma: Prospective, Multicenter, Exploratory Study[NCT04274270] | 60 participants (Anticipated) | Interventional | 2020-04-01 | Not yet recruiting | |||
| Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer[NCT03700333] | Phase 3 | 120 participants (Anticipated) | Interventional | 2018-10-20 | Not yet recruiting | ||
| Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992[NCT01880515] | Phase 2 | 107 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2[NCT01542437] | Phase 2 | 66 participants (Actual) | Interventional | 2012-01-31 | Active, not recruiting | ||
| A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer[NCT01874678] | 45 participants (Actual) | Interventional | 2011-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sum of participants who experienced any grade rash according to the Common Toxicity Criteria for Adverse Effects (CTCAE) V4.0, from the initiation of BIBW2992 compared to week 8. (NCT01880515)
Timeframe: Percentage of adverse events at week 8
| Intervention | Percentage of Patients w/any grade rash (Number) |
|---|---|
| Tetracycline | 44.5 |
| No Tetracycline | 75.5 |
From the start of consumption of BIBW 2992 to the date progression or last follow up (NCT01880515)
Timeframe: Participants will be followed for the duration of the treatment, an average of 8 weeks.
| Intervention | months (Median) |
|---|---|
| Tetracycline | 8.1 |
| No Tetracycline | 12.3 |
11 reviews available for oxonic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Meta-analysis for the efficacy of S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Clinic | 2017 |
S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modalit | 2018 |
S-1 plus cisplatin with concurrent radiotherapy for stage III non-small cell lung cancer: A meta-analysis (PRISMA) of randomized control trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Comb | 2018 |
Efficacy of S-1 in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S | 2014 |
S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; H | 2016 |
Meta-analysis Exploring the Effectiveness of S-1-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Combinations; Humans; | 2017 |
S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2009 |
UFT and S-1 for treatment of primary lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; | 2010 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Be | 2005 |
[Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer].
Topics: Administration, Oral; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, N | 2006 |
[Combination therapy with S-1 plus docetaxel (DOC) for previously treated patients with non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Pha | 2006 |
90 trials available for oxonic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Feasibility of postoperative adjuvant chemotherapy using carboplatin plus S-1 in completely resected non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2019 |
Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco | 2020 |
Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2019 |
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2020 |
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2021 |
Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcino | 2017 |
Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lu | 2017 |
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2017 |
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; C | 2018 |
Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free S | 2018 |
A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; C | 2018 |
A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug | 2018 |
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 2018 |
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2019 |
Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2019 |
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2019 |
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dis | 2019 |
Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 2019 |
Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell | 2019 |
Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemothera | 2013 |
Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Feasibility study of adjuvant chemotherapy of S-1 and carboplatin for completely resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemothe | 2013 |
[Series: Clinical study from Japan and its reflections; randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2013 |
Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 2013 |
Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dr | 2013 |
Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dis | 2014 |
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2014 |
Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non- | 2014 |
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; | 2014 |
Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combi | 2014 |
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2015 |
S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2015 |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chem | 2015 |
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; D | 2015 |
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell | 2015 |
Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell L | 2015 |
Prognostic Impact of the ABCC11/MRP8 Polymorphism in Adjuvant Oral Chemotherapy with S-1 for Non-Small Cell Lung Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; ATP-Binding C | 2016 |
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dr | 2016 |
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Non-Small-Cell Lung; Cisplatin | 2016 |
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcino | 2016 |
S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cis | 2016 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |
Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2009 |
Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 2008 |
Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dru | 2008 |
Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cel | 2009 |
A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Com | 2009 |
Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 2009 |
A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non- | 2009 |
A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Co | 2009 |
Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small cell lung cancer-LOGIK 0601 study.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combin | 2010 |
Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2009 |
Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2010 |
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; D | 2010 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease | 2010 |
Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2010 |
A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2010 |
A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2011 |
Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease | 2011 |
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma | 2010 |
Pooled analysis of S-1 trials in non-small cell lung cancer according to histological type.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; | 2010 |
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2010 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; | 2011 |
Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Fr | 2011 |
Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Large Ce | 2011 |
Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Surviv | 2011 |
An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 2011 |
S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2011 |
Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Com | 2012 |
A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiother | 2012 |
Pharmacokinetic study of weekly (days 1-5) low-dose S-1 in patients with non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small | 2012 |
A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Topics: Administration, Oral; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-C | 2012 |
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dose-Respo | 2013 |
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell | 2012 |
Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Carcinoma, Non-Small-Ce | 2012 |
Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free S | 2012 |
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2013 |
Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2013 |
A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: a report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Administration | 2014 |
S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2004 |
[Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-C | 2006 |
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; | 2001 |
Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; | 2001 |
56 other studies available for oxonic acid and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A potential novel drug combination for adjuvant therapy in lung cancer: reflections on an early phase of clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoth | 2019 |
S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-S | 2020 |
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2020 |
Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Car | 2020 |
A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Humans; Lung Neo | 2020 |
Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, N | 2021 |
Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; | 2017 |
Correlation of Expression Levels of Copper Transporter 1 and\
Thymidylate Synthase with Treatment Outcomes in Patients\
with Advanced Non-small Cell Lung Cancer Treated with\
S-1/Carboplatin Doublet Chemotherapy
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2018 |
Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; | 2018 |
A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies | 2018 |
A retrospective study of concurrent radiotherapy plus S-1 for treating advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2018 |
[Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated
with More Than Two Lines of Chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Female; Fluor | 2018 |
A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer: A protocol for a systematic review of randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Co | 2019 |
Spinal infarction related to the adjuvant chemotherapy for surgically resected non-small cell lung cancer: report of a case.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cel | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Comb | 2013 |
Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2013 |
[A case of recurrent non-small cell lung cancer successfully treated with multiple modality therapies including S-1 monotherapy as fifth-line chemotherapy hospital)].
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Combinations; Hum | 2013 |
Clinicopathological factors affecting progression-free survival of patients with previously treated advanced non-small cell lung cancer after S-1 therapy with or without bevacizumab.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites | 2014 |
Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2015 |
[Three cases of long-term control of non-small-cell lung cancer via S-1 monotherapy in elderly patients].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combi | 2015 |
[An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell | 2015 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large | 2016 |
Induction S-1+Concurrent Radiotherapy Followed by Surgical Resection of Locally Advanced Non-small-cell Lung Cancer in an Elderly Patient.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Combi | 2016 |
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; D | 2016 |
Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Dr | 2016 |
[A case of elderly non-small cell lung cancer effectively treated by combined chemotherapy of gemcitabine and S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; D | 2008 |
TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumo | 2008 |
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combin | 2009 |
[Effective gemcitabine plus S-1 treatment in elderly non-small cell lung cancer patients with multiple bone metastases].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Sm | 2009 |
[A case of non-small cell lung cancer with EGFR mutation responding to S-1 after a therapy with gefitinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; | 2009 |
[S-1 activity in non-small cell lung cancer in clinical practice].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2009 |
[S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Combi | 2009 |
Successful treatment of refractory bronchioloalveolar carcinoma with S-1 (oral fluoropyrimidine).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung | 2009 |
[Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combin | 2009 |
[A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Moda | 2010 |
Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; | 2010 |
Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lun | 2010 |
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cy | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-C | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-C | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-C | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-C | 2010 |
[A case of non-small cell lung cancer responding to S-1 over a year].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Co | 2010 |
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcino | 2011 |
[A case of long-term survival after resection of aortic arch for locally advanced non-small cell lung cancer with induction chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Carcinoma, Non-Small-Cell Lung; Cis | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2012 |
Concurrent chemoradiotherapy using cisplatin plus S-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: a single-center feasibility study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 2011 |
Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2012 |
[Two cases of long-term response treated by S-1 with concurrent radiotherapy followed by S-1 treatment for non-small cell lung cancer patients].
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Comb | 2012 |
Preoperative chemoradiotherapy using cisplatin plus S-1 can induce downstaging in patients with locally advanced (stage III) non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2012 |
A retrospective study of the novel combination of paclitaxel and S1 for pretreated advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease | 2012 |
[An advanced aged case of intrapulmonary metastasis of non-small cell lung cancer successfully controlled with S-1 capsule therapy alone for an extended period].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Drug Administrat | 2007 |
The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylas | 2008 |
[Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dru | 2008 |
The unanswered question: what is the determinant of S-1 pharmacokinetics?
Topics: Alleles; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Asian People; Body Size; Ca | 2008 |